

GovX, Inc. (website: [govxinc.com](https://govxinc.com)) is a public biotechnology company dedicated to developing vaccines and anti-viral therapies for infectious diseases using its patented Modified Vaccinia Ankara – Virus Like Particle (MVA-VLP) platform technology. Based in the United States, GovX focuses on addressing pressing global health threats by advancing a robust pipeline of candidates targeting a range of viral diseases, including COVID-19, smallpox, and monkeypox, among others. The company's technology platform leverages the versatile MVA-VLP system designed to evoke a strong, durable, and highly targeted immune response, positioning GovX at the forefront of preventative treatments and public health solutions in the biotech industry.